NCT04123626View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

June 7, 2022

Study Completion Date

June 7, 2022

Conditions
Autosomal Dominant Retinitis PigmentosaEye DiseasesEye Diseases, HereditaryRetinal DystrophiesRetinal DiseaseRetinitisVision TunnelVision Disorders
Interventions
DRUG

QR-1123

unilateral IVT injection

OTHER

Sham procedure

Sham procedures (i.e. no penetration of the globe) closely mimic the active injection and serve to mask subjects to treatment assignment

Trial Locations (5)

32607

VitreoRetinal Associates, Gainesville

40536

Shriners UK Ophthalmology - University of Kentucky, Lexington

75231

Retina Foundation of the Southwest, Dallas

80045

Sue Anschutz-Rogers Eye Center, University of Colorado - Dept. of Ophthalmology, Aurora

97239

Casey Eye Institute, OHSU, Portland

Sponsors

Lead Sponsor

ProQR Therapeutics
All Listed Sponsors
lead

ProQR Therapeutics

INDUSTRY

NCT04123626 - A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene | Biotech Hunter | Biotech Hunter